Get the Stockscreener App
6.03
2.20%
0.13
After Hours:
6.06
0.03
+0.50%
Savara Inc stock is traded at $6.03, with a volume of 1.54M.
It is up +2.20% in the last 24 hours and up +15.96% over the past month.
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
See More
Previous Close:
$5.90
Open:
$5.9
24h Volume:
1.54M
Relative Volume:
1.00
Market Cap:
$1.24B
Revenue:
-
Net Income/Loss:
$-129.48M
P/E Ratio:
-10.80
EPS:
-0.5584
Net Cash Flow:
$-106.97M
1W Performance:
+5.98%
1M Performance:
+15.96%
6M Performance:
-4.74%
1Y Performance:
+172.85%
1-Day Range:
$5.845
$6.04
1-Week Range:
$5.60
$6.195
52-Week Range:
$1.98
$7.005
Savara Inc Stock (SVRA) Company Profile
Name
Savara Inc
Sector
Industry
Phone
51285113796
Address
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
6.03 | 1.21B | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Savara Inc Stock (SVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-20-24 | Initiated | Wells Fargo | Overweight |
| Nov-13-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-24 | Initiated | JMP Securities | Mkt Outperform |
| Nov-07-23 | Initiated | Guggenheim | Buy |
| May-16-23 | Upgrade | Jefferies | Hold → Buy |
| Mar-31-23 | Downgrade | Jefferies | Buy → Hold |
| Mar-16-21 | Initiated | Piper Sandler | Overweight |
| Mar-15-21 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-13-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-13-19 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Aug-13-18 | Resumed | ROTH Capital | Neutral |
| Jan-03-18 | Initiated | Ladenburg Thalmann | Buy |
| Sep-27-17 | Resumed | ROTH Capital | Buy |
| Sep-22-17 | Initiated | Jefferies | Buy |
| Sep-11-17 | Initiated | JMP Securities | Mkt Outperform |
View All
Savara Inc Stock (SVRA) Latest News
Class Action Lawsuit Alert: Levi & Korsinsky Reminds Savara Inc. (SVRA) Investors of November 7, 2025 Deadline - The National Law Review
Levi & Korsinsky Notifies Savara Inc. (SVRA) InvestorsLead Plaintiff Deadline on November 7, 2025 - The National Law Review
Investors in Savara Inc. (SVRA): Protect Your RightsContact Levi & Korsinsky Before November 7, 2025 - The National Law Review
Savara, Inc. Actuals & Estimates (FWB:YB4P) - TradingView
SVRA Forecast — Price Target — Prediction for 2027 - TradingView
What Does the FDA's Priority Review Mean for Savara's MOLBREEVI - Kavout | AI
Savara, Inc. Actuals & Estimates (SWB:YB4P) - TradingView
YB4P Forecast — Price Target — Prediction for 2027 - TradingView
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Savara CFO David Lowrance sells $2.24m in company stock By Investing.com - Investing.com Australia
Form 4 Savara Inc For: 22 June By Investing.com - Investing.com Nigeria
Savara CFO David Lowrance sells $2.24m in company stock - Investing.com
Savara (SVRA) CFO exercises 580K options and sells 394K shares in Form 4 - Stock Titan
Form 144 Savara Inc For: 22 June By Investing.com - Investing.com South Africa
[144] Savara Inc SEC Filing - Stock Titan
Does Savara’s Expanded Share Pool and CFO Shift Reframe Its Capital Strategy Narrative (SVRA)? - simplywall.st
Savara StockLong-term pipeline story in rare lung disease - AD HOC NEWS
Savara Grants Equity Awards to New Hires Amid Growth Push - MyChesCo
Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Savara Shifts Finance Leadership Ahead of Key Drug Milestone - MyChesCo
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Savara Inc (SVRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Savara Inc (SVRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Savara Inc (SVRA) Institutional Confidence - TradingKey
Savara (SVRA) Proxy filing Summary - Quartr
What Is Driving Attention Toward Savara’s Rare Disease Strategy? - Kalkine Media
Savara: Lowrance Will Remain Available in Advisory Capacity >SVRA - Moomoo
Savara Announces New Employment Inducement Grant - Business Wire
How Investors Are Reacting To Savara (SVRA) Doubling Share Authorization And Reshaping Its CFO Role - simplywall.st
Savara shareholders approve share increases and executive changes at annual meeting - Investing.com Australia
Savara (SVRA) Announces Leadership Changes in Finance Department - GuruFocus
Savara shareholders approve share increases and executive changes at annual meeting By Investing.com - Investing.com South Africa
Savara Expands Share Capital and Updates Executive Leadership - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Savara CFO Dave Lowrance steps down; COO Robert Lutz takes on CFO role amid leadership reshuffle - Pluang
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role By Investing.com - Investing.com Australia
Savara CFO Dave Lowrance to step down, Robert Lutz to expand role - Investing.com Australia
Savara Announces Chief Financial And Administrative Officer Transition - TradingView
Savara (SVRA) expands share capacity and appoints Robert Lutz as CFO/COO - Stock Titan
Savara Announces Chief Financial and Administrative Officer Transition - The Joplin Globe
Savara Inc. Announces Step Down of Dave Lowrance as Chief Administrative Officer, Effective July 15, 2026 - marketscreener.com
Savara Inc Stock (SVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):